INTRODUCTION
Acute lactic acidosis occurring in patients with sepsis or low-flow states is associated with cellular dysfunction and heightened mortality. 1 Elimination or control of the triggering conditions remains the only effective therapy. Often base is prescribed, but its utility remains unproven. 2 Because management of the triggering conditions can be challenging, effective treatment remains elusive.
In this Acid-Base and Electrolyte Teaching Case, a patient with severe sepsis and lactic acidosis is presented. We discuss advances in the pathophysiology of lactic acidosis, 3 thus providing a framework for a future targeted approach to treatment.
CASE REPORT

Clinical History and Initial Laboratory Data
A 54-year-old white man with a history of alcohol abuse, alcoholic cirrhosis, depression, polysubstance abuse, and pancreatitisinduced diabetes mellitus was admitted to the hospital with palpitations, hyperventilation, and altered mental status. He reported no recent alcohol or drug use. Medications included insulin, simvastatin, and fish oil. Physical examination revealed blood pressure of 162/95 mm Hg without orthostatic changes, temperature of 99 F, pulse rate of 85 beats/min, and respirations of 18 breaths/min. Six hours later, he became tachycardic, blood pressure decreased to 105/50 mm Hg, and he developed a temperature of 101 F.
Subsequently, he developed oliguria and severe acidemia with a marked elevation in blood lactate concentration. Admission and subsequent laboratory findings are shown in Table 1 .
Additional Investigations
Blood cultures were negative. Computed tomography of the chest and abdomen was unremarkable. An exploratory laparotomy revealed no evidence of intestinal ischemia.
Diagnosis
Severe sepsis; acute kidney injury; acute lactic acidosis; alcoholic cirrhosis; hypernatremia.
Clinical Follow-up
Antibiotics were administered to treat the suspected infection, and crystalloids and vasopressors were given to support the circulation. Because of kidney failure and the accompanying lactic acidosis, continuous venovenous hemodialysis therapy was initiated. Blood pressure remained stable at 120/70 mm Hg, and blood lactate level decreased to 5 mEq/L and then remained between 4 and 6 mEq/L for the rest of the hospitalization. He was evaluated for a liver transplant, but was rejected owing to serious comorbid conditions. On hospital day 8, he died.
DISCUSSION
This patient with severe sepsis and liver disease had a precipitous decrease in serum bicarbonate concentration to 10 mEq/L and blood pH to 7.15 and an increase in blood lactate level to 20 mEq/L. These findings fulfill the classic definition of acute lactic acidosis: blood lactate level $ 5 mEq/L, blood pH # 7.35, and serum bicarbonate concentration # 20 mEq/L. 4 He also had coexisting respiratory acidosis because the decrease in PaCO 2 was less than expected for the prevailing serum bicarbonate concentration. The change in anion gap divided by change in bicarbonate (DAG/DHCO 3 -) of 1.3 is consistent with acute lactic acidosis alone or a combined metabolic alkalosis and metabolic acidosis. 5, 6 The former diagnosis seemed most likely because no conditions promoting the development of metabolic alkalosis were present (diuretics, vomiting, or gastric drainage).
Although both acidemia and hypobicarbonatemia were present, these abnormalities are sometimes absent in hyperlactatemic patients because of coexisting acidbase disorders, such as metabolic alkalosis or respiratory alkalosis. 3 Nonetheless, hyperlactatemia implies the presence of lactic acidosis, in which there is net addition of lactate and protons to the body fluids. 3, 7 Limited data suggest that at a given blood lactate level, acidemia is associated with worse clinical outcomes 8, 9 ; however, further work is required on this important issue.
Sustained hyperlactatemia in sepsis or low-flow states carries mortality $ 60%.
1,10 Next, we first provide a brief description of the current therapy of lactic acidosis and then suggest potential future therapies that derive from advances in our understanding of the pathophysiology of the disorder.
Resuscitative efforts to support the circulation and ventilation are the first steps in treating lactic acidosis. The optimal crystalloid solution for fluid resuscitation remains under investigation, with proponents of both saline and balanced-salt solutions. 11, 12 Using central venous pressure and oxygen saturation to guide therapy is controversial. 13, 14 Vasopressors and inotropic agents should be administered, as required, but excessive use should be avoided to prevent aggravation of hyperlactatemia from reduction in tissue perfusion or overstimulation of the b 2 -adrenoceptor. Optimized delivery of oxygen to tissues depends on the adequacy of cardiac output, PO 2 , and hemoglobin concentration. Invasive ventilation might be required to ensure adequate PO 2 and prevention of hypercapnia.
Swift initiation of cause-specific measures is key to effective management of acute lactic acidosis. In sepsis, early administration of appropriate antibiotics and control of the infection source are paramount.
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An exploratory laparotomy was performed in our patient because of concerns about intestinal ischemia.
When present, severe acidemia (blood pH , 7.2) might impair cardiovascular function and blood flow.
6,16 Therefore, many clinicians will administer base to increase blood pH to a presumed safe level (pH w 7.2). 6 Because reductions in intracellular pH and interstitial pH are considered the key effectors of cellular dysfunction in acute metabolic acidosis, base therapy aims at increasing intracellular pH and interstitial pH, along with blood pH. 17 Sodium bicarbonate has been the most commonly used base (hypertonic or preferably isotonic solution). However, in the majority of studies, it does not improve cardiac function or reduce mortality [18] [19] (Table 2 ). This failure has largely been ascribed to 2 adverse effects. First, carbon dioxide is generated as protons are buffered by bicarbonate. The carbon dioxide rapidly traverses the cell membrane, whereas bicarbonate movement into the cell is hindered, with the potential for producing an intracellular respiratory acidosis. 20, 21 Importantly, not all studies showed intracellular acidification after bicarbonate administration.
22 This is most likely to occur when large amounts of bicarbonate are given rapidly, particularly to patients with severe circulatory failure, promoting carbon dioxide accumulation in tissues. Perhaps the use of bicarbonate should be individualized. If the circulation is adequate or only moderately impaired, bicarbonate administration might [23] [24] [25] Second, an increase in pH increases binding of calcium to circulating protein, thereby reducing the ionized fraction and depressing cardiovascular function. 18 This alteration should occur with any base that increases the pH of critical compartments and is compounded by evidence that calcium concentration can be decreased in lactic acidosis itself. 26 Both these adverse effects can be minimized. Hyperventilation to reduce carbon dioxide accumulation and infusion of calcium to stabilize calcium concentration increased intracellular pH and blood pH, improved myocardial function, and reduced the quantity of vasopressors necessary to maintain blood pressure in rats with hemorrhage-induced lactic acidosis administered bicarbonate. 16, 27 When base is given, the clinician should try to maintain blood pH at w7.2. This pH was chosen because lower values depressed cardiac contractility in animals, 28 suppressed the contraction of myocardial fibrils isolated from failing hearts of humans, 27 and was associated with increased mortality. 8 Increasing blood pH to w7.2 should improve cardiac contractility and restore responsiveness of the myocardium and peripheral vessels to endogenous and infused catecholamines. 16, 29, 30 To calculate the quantity of bicarbonate required to increase serum bicarbonate concentration to a given amount, we assume that administered bicarbonate is distributed in 50% body weight expressed in kilograms (bicarbonate space). This is only an estimate, and monitoring of acid-base parameters every few hours is required for potential dose adjustment. Given our patient's hypernatremia, bicarbonate should be administered as an isotonic solution.
Alternatively, administration of bases that do not generate substantial quantities of carbon dioxide (or preferably consume it) during the buffering process might be more likely to improve cellular function. Table 3 shows the benefits and limitations of buffers that might be used for this purpose.
THAM buffers protons by virtue of its amine group. In contrast to sodium bicarbonate, it does not generate carbon dioxide. It might lower PCO 2 .
31 It is as effective as sodium bicarbonate in increasing serum bicarbonate concentration 32 and when given to individuals with carbon dioxide retention, improves cardiac contractility in parallel with improvement in acid-base balance. 33 To eliminate acid, THAM has to be removed from the body. This is easily accomplished when kidney function is normal, but is limited as kidney function declines. As a small molecule, THAM is dialyzable. Therefore, decreased kidney function might not prevent its use. Because it is the only other base approved for treatment of acid-base disorders, further studies of the benefits and complications of THAM are warranted.
Balanced-salt solutions containing organic acid anions as the source of base, such as lactated Ringer solution and Plasma-Lyte (Baxter Healthcare), have been recommended for fluid resuscitation, 11 but their use in the treatment of metabolic acidosis has not been examined rigorously. Also, their use in individuals with severe liver disease might not be appropriate because of the limited metabolism of the organic acid anion. Thus, although infusion of 1 L of lactated Ringer solution produces only a minor increment in blood lactate level in individuals with normal liver function, 34 the impact is likely to be magnified in patients with severe liver disease. This could be important because in vitro studies suggest that lactate could have a depressant effect on cardiovascular function. 35 Disodium carbonate also consumes carbon dioxide in the process of buffering. Therefore, a 1:1 mixture of sodium bicarbonate and disodium carbonate, termed Carbicarb, was developed in the 1980s. 36 In animal experiments, it improved acid-base parameters of blood and the intracellular compartment while generating little or no carbon dioxide. 37 A single study of patients with mild metabolic acidosis failed to demonstrate a significant advantage of Carbicarb compared to sodium bicarbonate, 38 and it has never been introduced into clinical practice. Given its overall profile, further examination of this base seems warranted.
Dialysis is an effective method of delivering large quantities of base. During dialysis, base in the dialysate diffuses into the patient's blood. In addition, base can be administered intravenously during the dialysis procedure. Dialysis has the advantage that extracellular fluid volume and serum osmolality, 2 parameters that can be perturbed by administering hypertonic sodium bicarbonate, can be readily controlled. Also, by using a dialysate calcium concentration $ 3.0 mEq/L, 39 sufficient calcium can be delivered to stabilize serum calcium concentration. Although intermittent dialysis can be used, we prefer continuous renal replacement therapy (particularly continuous venovenous hemodialysis). With this modality, the quantity and rate of base delivered can be modulated to minimize any rapid changes in carbon dioxide generation and acid-base parameters. 40 To be sure, even relative alkalinization of body fluids by administered base, including by dialysis, augments lactic acid production by stimulating 6-phosphofructokinase. Nonetheless, dialysis can decrease hyperlactatemia and ameliorate acidemia. 41 Dialysis removes substances that can produce severe metabolic acidosis, such as toxic alcohols and metformin, and has been effective in the treatment of both disorders. 42, 43 Lactate is also removed by dialysis, although the quantity is relatively small compared to the amount produced. 44 We have a low threshold for initiating dialysis therapy in patients with lactic acidosis and decreased kidney function, but controlled studies to determine its risk to benefit ratio are warranted.
The therapies discussed heretofore have not decreased morbidity and mortality in patients with lactic acidosis. However, measures based on a deeper understanding of the pathogenesis of lactic acidosis and cellular injury might improve the clinical outcomes.
As shown in Fig 1, hyperlactatemia occurs when lactate production exceeds its consumption. In low-flow states and sepsis, excess net production of lactic acid can be driven by 2 distinctly different mechanisms: First, tissue hypoxia impairs mitochondrial oxidation and causes both overproduction and underutilization of lactate. When acidemia coexists with hypoxia, the liver can be converted into a net lactate-producing organ. Even if systemic oxygen delivery is not sufficiently low to induce global hypoxia, associated microcirculatory dysfunction can reduce oxygen extraction, causing regional tissue hypoxia and hyperlactatemia. Tissue hypoxia is often considered the leading mechanism of increased net lactic acid production.
The second mechanism is aerobic glycolysis (stimulation of glycolysis by factors other than tissue hypoxia or impaired oxidative phosphorylation by chemical agents or drugs) stimulated by high levels of circulating epinephrine. By binding to the b 2 -adrenoceptor on the plasma membrane, epinephrine increases the glycolytic flux both directly and by stimulation of the ubiquitous adenosine triphosphatase sodium/potassium pump (Na 1 /K 1 -ATPase) and the resultant consumption of ATP. 45 An increase in lactate utilization also occurs, but falls short of the abundant production. This is considered the primary mechanism of hyperlactatemia in the hyperdynamic stage of sepsis. 46 However, both aerobic glycolysis and tissue hypoxia often contribute to the hyperlactatemia in sepsis and low-flow states. 47 Finally, in hemodynamically stable patients with sepsis, lactate clearance by the liver can be decreased, possibly through pyruvate dehydrogenase inhibition. In sepsis and low-flow states, chronic liver disease further compromises lactate clearance. However, chronic liver disease alone causes only minimal hyperlactatemia. 48, 49 Kidney failure adds to the impairment in lactate clearance.
Theoretically, any one of these mechanisms could predominate in a given patient, compelling a variable approach to treatment. If only tissue hypoxia was present, measures to preserve tissue oxygen delivery might be emphasized. If microvascular dysfunction was present, rescuing the microcirculation with dobutamine, acetylcholine, nitroglycerin, or novel agents could improve the hyperlactatemia independent of systemic hemodynamics. 50 By contrast, if aerobic glycolysis was dominant, blocking the release or the effects of epinephrine could be beneficial. Adrenoceptor blockade can lessen hyperlactatemia 51 ,52 even if ] ratio shifts the equilibrium of the lactate dehydrogenase (LDH) reaction toward lactate. (C) Lactate accumulation in the hyperdynamic stage of sepsis. Glycolysis acceleration is linked to increased activity of the sarcolemmal adenosine triphosphatase sodium/potassium pump (Na 1 /K tive phosphorylation and thus lactate utilization is increased in this setting but falls short of the level of glycolysis resulting in hyperlactatemia. This type of stimulated glycolysis has been dubbed aerobic glycolysis to indicate that it does not depend on tissue hypoxia. Evidence suggests that the glycolytic pathway linked to the sarcolemmal Na 1 /K 1 -ATPase activity is functionally compartmentalized from that directed to oxidative metabolism (not shown). Liver dysfunction or decreased kidney function can also reduce lactate clearance and contribute to hyperlactatemia generated by both main mechanisms. Abbreviations: acetyl CoA, acetyl coenzyme A; ADP, adenosine diphosphate; cAMP, cyclic adenosine monophosphate; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; TCA, tricarboxylic acid. Reproduced and modified from Kraut and Madias 3 with permission of the Massachusetts Medical Society.
it decreases oxygen delivery. 53 If both mechanisms were operative, targeting each might maximize benefit.
At present, tools to identify the mechanisms of net lactic acid production are not in clinical use, although some are under study. For example, handheld devices permitting direct visualization of the microcirculation are undergoing clinical study. 54 Further research to promote a mechanism-specific approach could improve clinical outcomes by using measures targeted to operative mechanisms while avoiding therapies that are futile or even harmful.
Identifying the pathways of cellular dysfunction could reveal specific targets for treatment. When present, hypoxia impairs vital cellular processes and causes cell death. Delivering adequate oxygen will improve cell function along with stemming net lactic acid production.
The reduction in intracellular pH during lactic acidosis can produce cell injury by activating the sodium/hydrogen exchanger 1 (NHE1), an exchanger ubiquitously present in the cell membrane. 55 Administration of selective inhibitors of NHE1 to experimental animals with lactic acidosis due to severe volume depletion, sepsis, or trauma improved cardiac function, reduced inflammation, ameliorated lactic acidosis, and decreased mortality. 56 The injurious cellular effects of NHE1 activation in these models are presumed to emanate from the resulting sodium influx that cannot be countered by the suppressed Na 1 /K 1 -ATPase activity consequent to hypoxia-induced ATP depletion. If generation of lactic acidosis is largely driven by aerobic glycolysis, the prevailing b 2 -stimulation of Na 1 /K 1 -ATPase activity might prevent sodium overload, thereby eliminating the indication for NHE1 inhibition. Although limited work in experimental sepsis suggests benefit, 57, 58 additional research is needed to test the utility of NHE1 inhibition in nonhypoxic models of lactic acidosis. Certainly, the beneficial effect of NHE1 inhibition might be multifactorial. Given the encouraging results with NHE1 inhibition, further studies in experimental models of acute lactic acidosis are warranted. If these prove successful, studies in humans would be indicated.
The importance of advancing our understanding of the cellular dysfunction accompanying lactic acidosis is highlighted by the disappointing results of the dichloroacetate trial. 59 Although dichloroacetate, a stimulator of pyruvate dehydrogenase, resulted in significant moderation of hyperlactatemia, it failed to alter either hemodynamics or survival of patients with acute lactic acidosis. 59 The role of lactate itself on cellular function remains controversial. Studies of isolated frog heart demonstrated a correlation between an increase in ambient lactate concentration and impaired cardiac function. 60 However, infusion of large amounts of sodium lactate, which increased blood lactate levels up to 15 mEq/L, did not depress cardiac output in patients following heart transplantation. 61 Further studies are necessary to examine the potential merits of lactate removal.
Effective treatment of lactic acidosis mandates appropriate monitoring of patients. Hemodynamic status, hemoglobin level, and arterial oxygen saturation should be assessed. There is ongoing controversy about the use of protocol-based targets or central venous catheterization, particularly in patients with sepsis. 15, 62 Sustained hyperlactatemia has adverse prognostic value and thus blood lactate levels should be monitored. Measurement of either arterial or venous lactate is acceptable because the values are essentially interchangeable. 63 Some experts have advocated determination of lactate clearance using serial blood lactate determinations to judge the effectiveness of treatment. 64 The goal of lactate-guided therapy is normalization of blood lactate level. The value of this approach remains unproven.
Assessment of the acid-base milieu of tissues is important to guide therapy. Usually this is accomplished by measuring arterial blood gases, but venous The development of acute lactic acidosis in patients with sepsis or low-flow states is associated with a marked increase in mortality. Aggressive resuscitation and elimination or control of the triggering conditions are the mainstay of therapy. A decrease in interstitial and intracellular pH can contribute to cellular dysfunction. Administration of base as sodium bicarbonate does not reduce mortality or improve cardiovascular function, even when blood pH is increased. Failure of HCO 3 2 to improve outcomes is attributed to generation of excess CO 2 and decrease in ionized Ca 21 . Hyperventilation to lessen CO 2 accumulation and administration of Ca 21 to stabilize blood Ca 21 might allow the positive effects of HCO 3 2 therapy to be expressed.
Alternatively, administration of bases that do not generate CO 2 or even consume it, such as THAM or Carbicarb, could improve cellular function. Disparate mechanisms can lead to excessive lactic acid generation, including tissue hypoxia and epinephrinedependent stimulation of Na 1 /K 1 -ATPase. Measures targeting these mechanisms could improve the treatment of lactic acidosis. Activation of NHE1 with a resultant increase in cellular sodium and calcium is deleterious in animal studies, and administration of selective inhibitors of NHE1 improves cardiovascular function and reduces mortality. Further examination of the factors involved in producing cellular injury in acute lactic acidosis is indicated to facilitate the development of targeted therapy. Lactate-guided therapy might improve clinical outcomes, and the potential benefits of this approach need to be examined further.
Abbreviations: Na 1 /K 1 -ATPase, adenosine triphosphatase sodium/potassium pump; NHE1, sodium/hydrogen exchanger 1; THAM, tris-hydroxymethyl aminomethane.
blood gases are increasingly used. In individuals without severe hypoperfusion, either approach is acceptable. 65 However, under conditions of severe tissue hypoperfusion, there is marked disparity between the pH and PCO 2 of arterial blood and those of venous blood (and the tissues). 23 Nonetheless, the clinical value of monitoring central venous blood gases in such patients remains unproven. Of course, monitoring of arterial blood gases is required in the critically ill for assessing pulmonary gas exchange. Other measures of tissue acid-base milieu, such as gastric tonometry and sublingual capnometry, are also under investigation. The role of these measures in monitoring patients with lactic acidosis remains undefined.
In summary, acute lactic acidosis carries an ominous prognosis. Rapid diagnosis and initiation of therapy is essential to reducing mortality. Newer strategies, such as probing the underlying mechanisms and applying targeted therapy, as well as administration of selective inhibitors of NHE1, could be beneficial and warrant further study. Lactate-guided therapy with the goal of normalizing blood lactate levels (to ,2 mEq/L) has shown some benefit and remains under investigation. 66 Given the critical importance of this disorder in affecting clinical outcome, randomized controlled studies of various treatment regimens would be useful in establishing an evidence-based approach to treatment. Essential teaching points are summarized in Box 1.
